Autoimmune polyglandular syndrome type I. A case report.

Autoimmune polyglandular syndrome (APS) type I is a disorder that consists of three primary diseases: hypoparathyroidism (HPT), adrenocortical insufficiency (ACI) and chronic mucocutaneous candidiasis. Several other disorders may be associated. The diagnosis of APS type I was made in a 16-year-old patient with HPT, Hashimato's thyroiditis and ACI in our department. She has been observed for more than four years for other possible endocrine and non-endocrine disorders.

Adult extrarenal Wilms' tumor. A case report.

Wilms' tumor or nephroblastoma is a malignant tumor of childhood and there are less than 200 cases in adults reported in the literature. An extrarenal location is also a rare situation for these tumors. A 48-year-old patient, referred to our gynecology department because of an abdominal mass, was operated on with a preoperative diagnosis of a possible ovarian tumor. The diagnosis of an extrarenal Wilms' tumor (ERWT) was made pathologically. Since it is a very rare entity, ERWT of adult origin is presented and the related literature is reviewed.

Long-term effects of octreotide therapy on in-stent restenosis.

The purpose of this study was to assess the long-term effects of octreotide therapy on in-stent restenosis at 6-month follow-up coronary angiography and the clinical events after stenting. A randomized, double-blind, placebo-controlled trial was conducted to assess the effects of octreotide on restenosis after stenting. The patients ( n = 148) received either subcutaneous octreotide or placebo 1 h before the stenting procedure and then every 8 h for 3 weeks. Percent diameter stenosis was interpreted before and after stenting, and on a 6-month follow-up coronary angiogram by quantitative coronary angiography. The mean percent diameter stenosis of the octreotide group was significantly lower than that of the placebo group on the 6-month follow-up coronary angiograms (18.8% +/- 14.2% vs 35.0% +/- 19.2%, respectively; P = 0.001). The restenosis rate of the octreotide group was statistically lower than that of the placebo group (11.8% vs 26.4%, respectively; P << 0.05). With regard to major cardiovascular events, there was no significant difference between the octreotide and placebo groups. The administration of octreotide for treatment of in-stent restenosis results in a relatively low long-term angiographic restenosis rate and no significant acute effects on cardiovascular clinical events.